Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy

Cancers (Basel). 2020 Apr 10;12(4):940. doi: 10.3390/cancers12040940.

Abstract

Hyaluronic acid (HA) is a natural mucopolysaccharide and has many useful advantages, including biocompatibility, non-immunogenicity, chemical versatility, non-toxicity, biodegradability, and high hydrophilicity. Numerous tumor cells overexpress several receptors that have a high binding affinity for HA, while these receptors are poorly expressed in normal body cells. HA-based drug delivery carriers can offer improved solubility and stability of anticancer drugs in biological environments and allow for the targeting of cancer treatments. Based on these benefits, HA has been widely investigated as a promising material for developing the advanced clinical cancer therapies in various formulations, including nanoparticles, micelles, liposomes, and hydrogels, combined with other materials. We describe various approaches and findings showing the feasibility of improvement in theragnosis probes through the application of HA.

Keywords: anticancer agent; cancer therapy; hyaluronic acid; nanomedicine; receptors; theranosis.

Publication types

  • Review